The PLCO biorepository: Creating, maintaining, and administering a unique biospecimen resource

Reviews on Recent Clinical Trials

Volumn 10, Issue 3, 2015, Pages 212-222

  Carrick, Danielle M ^a   Black, Amanda ^a   Gohagan, John K ^b   Khan, Asia ^c   Pettit, Karen ^c   Williams, Craig ^d   Yu, Kelly ^a   Yurgalevitch, Susan ^c   Huang, Wen Yi ^a   Zhu, Claire ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c WESTAT   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

Biorepository; Biospecimen; Blood; Early marker; Etiologic; PLCO; Tissue

Indexed keywords

FORMALDEHYDE; PARAFFIN; TUMOR MARKER;

ARTICLE; BIOSPECIMEN; BLOOD SAMPLING; CANCER CENTER; CANCER REGISTRY; CANCER RESEARCH; CANCER SCREENING; CANCER TISSUE; CLINICAL DATA REPOSITORY; COHORT ANALYSIS; DATA PROCESSING; DATA STORAGE DEVICE; HEALTH CARE POLICY; HUMAN; INFORMATION PROCESSING; MOUTH CAVITY; PRIORITY JOURNAL; SAMPLING; BLOOD; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; ETHICS; FEMALE; HEALTH CARE FACILITY; HISTOLOGY; LUNG NEOPLASMS; MALE; MEDICAL RESEARCH; MULTICENTER STUDY (TOPIC); NATIONAL HEALTH ORGANIZATION; NEEDLE BIOPSY; NEOPLASMS; ORGANIZATION AND MANAGEMENT; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

BIOMARKERS, TUMOR; BIOMEDICAL RESEARCH; BIOPSY, NEEDLE; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MULTICENTER STUDIES AS TOPIC; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE BANKS; TISSUE EMBEDDING; UNITED STATES;

EID: 84946072987     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887110666150730121429     Document Type: Article

References (67)

1. Carrick DM, Mette E, Hoyle B, et al. The use of biospecimens in population-based research: a review of the National Cancer Institute's Division of Cancer Control and Population Sciences grant portfolio. Biopreserv Biobank 2014; 12: 240-5.
2. Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000; 21: 349S-55S.
3. Hayes RB, Sigurdson A, Moore L, et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res 2005; 592: 147-54.
4. Zhu CS, Pinsky PF, Kramer BS, et al. The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. J National Can Inst 2013; 105: 1684-93.
5. PLCO. PLCO Biorepository Blood Specimen Collection Protocols. 2014. Retrieved from: https: //www.plcostars.com/Public/ Documents/PLCO/BiospecimenCollectProtocol.pdf.
6. Hayes RB, Smith CO, Huang WY, Read Y, Kopp WC. Whole blood cryopreservation in epidemiological studies. Am Soc Prev Oncol 2002; 11: 1496-8.
7. IATA. IATA Dangerous Good Regulations (DGR). 2015. Retrieved from: http: //www.iata.org/publications/dgr/Pages/ index.aspx.
8. Zhu CS, Pinsky PF, Cramer DW, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res 2011; 4: 375-83.
9. PLCO. PLCO EEMS. 2014. Retrieved from: http: //www. plcostars.com.
10. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nature Gen 2007; 39: 870-4.
11. Landi MT, Chatterjee N, Yu K, et al. A Genome-wide Association Study of Lung Cancer Identifies a Region of Chromosome 5p15 Associated with Risk for Adenocarcinoma. Am J Human Gen 2009; 85: 679-91.
12. Peters U, Hutter CM, Hsu L, et al. Meta-analysis of new genomewide association studies of colorectal cancer risk. Human Gen 2012; 131: 217-34.
13. Wentzensen N, Black A, Jacobs K, et al. Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the prostate, lung, colorectal, and ovarian cancer screening trial. PloS One 2011; 6: e21731.
14. Purdue MP, Johansson M, Zelenika D, et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nature Gen 2011; 43: 60-5.
15. Rothman N, Garcia-Closas M, Chatterjee N, et al. A multi-stage genome-wide association study of bladder cancer identifies multi ple susceptibility loci. Nature Gen 2010; 42: 978-84.
16. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genomewide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Gen 2009; 41: 986-90.
17. De Vivo I, Prescott J, Setiawan VW, et al. Genome-wide association study of endometrial cancer in E2C2. Human Gen 2014; 133: 211-24.
18. Rajaraman P, Melin BS, Wang Z, et al. Genome-wide association study of glioma and meta-analysis. Human Gen 2012; 131: 1877- 88.
19. Cerhan JR, Berndt SI, Vijai J, et al. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Gen 2014; 46: 1233-8.
20. Berndt SI, Skibola CF, Joseph V, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Gen 2013; 45: 868-76.
21. Yeager M, Xiao N, Hayes RB, et al. Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Human Gen 2008; 124: 161- 70.
22. Parikh H, Deng Z, Yeager M, et al. A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33. Human Gen 2010; 127: 91-9.
23. Al Olama AA, Kote-Jarai Z, Berndt SI, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Gen 2014; 46: 1103-9.
24. Siddiq A, Couch FJ, Chen GK, et al. A meta-analysis of genomewide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 2012; 21: 5373- 84.
25. Campa D, Kaaks R, Le Marchand L, et al. Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J National Cancer Inst; 103: 1252-63.
26. Witte JS, Hoffmann TJ. Polygenic modeling of genome-wide association studies: an application to prostate and breast cancer. Omics: J Integ Biol 2011; 15: 393-8.
27. Machiela MJ, Chen CY, Chen C, et al. Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. Gen Epidemiol 2011; 35: 506-14.
28. Jiao S, Peters U, Berndt S, et al. Estimating the heritability of colorectal cancer. Human Mol Genet 2014; 23: 3898-905.
29. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Gen 2010; 42: 937-48.
30. Berndt SI, Gustafsson S, Magi R, et al. Genome-wide metaanalysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nature Gen 2013; 45: 501- 12.
31. Caporaso N, Gu F, Chatterjee N, et al. Genome-wide and candidate gene association study of cigarette smoking behaviors. PloS one 2009; 4: e4653.
32. Ahn J, Yu K, Stolzenberg-Solomon R, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010: ddq155. 155: 273-9.
33. Moy KA, Mondul AM, Zhang H, et al. Genome-wide association study of circulating vitamin D- binding protein. Am J Clin Nutr 2014; 99: 1424-31.
34. Cornelis MC, Monda KL, Yu K, et al. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet 2011; 7: e1002033.
35. Gong J, Hsu L, Harrison T, et al. Genome-wide association study of serum selenium concentrations. Nutrients 2013; 5: 1706-18.
36. Prescott J, Kraft P, Chasman DI, et al. Genome-wide association study of relative telomere length. PloS one 2011; 6: e19635.
37. Shiels MS, Engels EA, Shi J, et al. Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer 2012; 118: 5630-6.
38. Ryan BM, Zanetti KA, Robles AI, et al. Germline variation in NCF4, an innate immunity gene, is associated with an increased risk of colorectal cancer. Int J Cancer J Int du Cancer 2014; 134: 1399-407.
39. Huang WY, Berndt SI, Kang D, et al. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk. Cancer Epidemiol, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the Amer Soc Prev Oncol 2006; 15: 306-11.
40. Peters U, Hayes RB, Chatterjee N, et al. Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the Amer Soc Prev Oncol 2004; 13: 546-52.
41. Canzian F, Cox DG, Setiawan VW, et al. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet 2010; 19: 3873-84.
42. Church TR, Haznadar M, Geisser MS, et al. Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk. Int J Mol Epidemiol Genet 2010; 1: 295-309.
43. Berndt SI, Huang WY, Fallin MD, et al. Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma. Cancer Res 2007; 67: 1395-404.
44. Huang WY, Chatterjee N, Chanock S, et al. Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the Amer Soc Prev Oncol 2005; 14: 152-7.
45. Koutros S, Berndt SI, Sinha R, et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Cancer Res 2009; 69: 1877-84.
46. Michaud DS, Daugherty SE, Berndt SI, et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL- 8, and IL-10 and risk of prostate cancer. Cancer Res 2006; 66: 4525-30.
47. Moore LE, Huang WY, Chatterjee N, et al. GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the Amer Soc Prev Oncol 2005; 14: 1823-7.
48. Purdue MP, Hofmann JN, Colt JS, et al. A case-control study of peripheral blood mitochondrial DNA copy number and risk of renal cell carcinoma. PloS one 2012; 7: e43149.
49. Andreotti G, Karami S, Pfeiffer RM, et al. LINE1 methylation levels associated with increased bladder cancer risk in prediagnostic blood DNA among US (PLCO) and European (ATBC) cohort study participants. Epigenetics: J DNA Methyl Soc 2014; 9: 404-15.
50. Huang WY, Su LJ, Hayes RB, et al. Prospective study of genomic hypomethylation of leukocyte DNA and colorectal cancer risk. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the Amer Soc Prev Oncol 2012; 21: 2014-21.
51. Seow WJ, Cawthon RM, Purdue MP, et al. Telomere length in white blood cell DNA and lung cancer: a pooled analysis of three prospective cohorts. Cancer Res 2014; 74: 4090-8.
52. Kim C, Bassig BA, Seow WJ, et al. Pooled analysis of mitochondrial DNA copy number and lung cancer risk in three prospective studies. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the Amer Soc Prev Oncol 2014; 23: 2977-80.
53. Mirabello L, Huang WY, Wong JY, et al. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell 2009; 8: 405-13.
54. Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Nat Can Ins 2008; 100: 796-804.
55. Breyer BN, Huang WY, Rabkin CS, et al. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: Results from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int 2015.
56. Brock K, Huang WY, Fraser DR, et al. Low vitamin D status is associated with physical inactivity, obesity and low vitamin D intake in a large US sample of healthy middle-aged men and women. The J Ster Biochem Mol Biol 2010; 121: 462-6.
57. Cross AJ, Sinha R, Wood RJ, et al. Iron homeostasis and distal colorectal adenoma risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Prev Res 2011; 4: 1465-75.
58. Gunter MJ, Cross AJ, Huang WY, et al. A prospective evaluation of C-reactive protein levels and colorectal adenoma development. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the Amer Soc Prev Oncol 2011; 20: 537-44.
59. Huang WY, Hayes R, Pfeiffer R, et al. Sexually transmissible infections and prostate cancer risk. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the Am Soc Prev Oncol 2008; 17: 2374-81.
60. Purdue MP, Hofmann JN, Kemp TJ, et al. A prospective study of 67 serum immune and inflammation markers and risk of non- Hodgkin lymphoma. Blood 2013; 122: 951-7.
61. Shiels MS, Pfeiffer RM, Hildesheim A, et al. Circulating inflammation markers and prospective risk for lung cancer. J Nat Can Inst 2013; 105: 1871-80.
62. Trabert B, Pinto L, Hartge P, et al. Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecol Oncol 2014; 135: 297-304.
63. Guertin KA, Moore SC, Sampson JN, et al. Metabolomics in nutritional epidemiology: identifying metabolites associated with diet and quantifying their potential to uncover diet-disease relations in populations. Am J Clin Nutr 2014; 100: 208-17.
64. Landgren O, Albitar M, Ma W, et al. B-cell clones as early markers for chronic lymphocytic leukemia. New Eng J Med 2009; 360: 659-67.
65. Sigurdson AJ, Jones IM, Wei Q, et al. Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Carcinogenesis 2011; 32: 69-73.
66. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Nat Can Inst 2001; 93: 1054- 61.
67. PLCO. Biospecimen Use Guidelines. 2014. Retrieved from: https: //www.plcostars.com/Project/Plco/Documents/Biospecimen_UserG uide.pdf.